


• **Seifer DB, MacLaughlin DT, Penzias AS, Behrman HR, Asmundson L, Donahoe PK, Haning RVJ and Flynn SD (1993):** Gonadotropin releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid Mullerian-inhibiting substance and androgen content. J Clin Endocrinol Metab, 76: 711-714.

• **Sheehan MT (2004):** Polycystic Ovarian Syndrome: Diagnosis and Management Clinical Medicine & Research (2): 13-27.

• **Silfen ME, Manibo AM, McMahon DJ, Levine LS, Murphy AR, Oberfield SE (2001):** Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. J Clin Endocrinol Metabolol Metab 2001; 86: 2863-2868.


• **Strauss JF III and Dunaif A (1999):** Molecular mysteries of polycystic ovary syndrome. Mol Endocrinol; 13: 800-805.


• Taylor AE, McCourt B, Martin KA (1997): Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. *J Clin Endocrinol Metab*; 82: 2248-2256.


• Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ & Brinkworth GD (2009): The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with


